Literature DB >> 26526714

A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling.

Robert W Cowan1, Anirban Maitra2, Andrew D Rhim3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26526714      PMCID： PMC5161089          DOI： 10.1053/j.gastro.2015.10.028

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  27 in total

1.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Authors:  Andrew D Rhim; Paul E Oberstein; Dafydd H Thomas; Emily T Mirek; Carmine F Palermo; Stephen A Sastra; Erin N Dekleva; Tyler Saunders; Claudia P Becerra; Ian W Tattersall; C Benedikt Westphalen; Jan Kitajewski; Maite G Fernandez-Barrena; Martin E Fernandez-Zapico; Christine Iacobuzio-Donahue; Kenneth P Olive; Ben Z Stanger
Journal:  Cancer Cell       Date:  2014-05-22       Impact factor: 31.743

2.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

Authors:  Marina Lesina; Magdalena U Kurkowski; Katharina Ludes; Stefan Rose-John; Matthias Treiber; Günter Klöppel; Akihiko Yoshimura; Wolfgang Reindl; Bence Sipos; Shizuo Akira; Roland M Schmid; Hana Algül
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

3.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.

Authors:  Akihisa Fukuda; Sam C Wang; John P Morris; Alexandra E Folias; Angela Liou; Grace E Kim; Shizuo Akira; Kenneth M Boucher; Matthew A Firpo; Sean J Mulvihill; Matthias Hebrok
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

4.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

5.  Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis.

Authors:  Florian R Greten; Christoph K Weber; Tim F Greten; Günter Schneider; Martin Wagner; Guido Adler; Roland M Schmid
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

6.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Authors:  Yaqing Zhang; Wei Yan; Meredith A Collins; Filip Bednar; Sabita Rakshit; Bruce R Zetter; Ben Z Stanger; Ivy Chung; Andrew D Rhim; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

7.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

8.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Authors:  Kristopher K Frese; Albrecht Neesse; Natalie Cook; Tashinga E Bapiro; Martijn P Lolkema; Duncan I Jodrell; David A Tuveson
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

10.  Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Authors:  Mara H Sherman; Ruth T Yu; Dannielle D Engle; Ning Ding; Annette R Atkins; Herve Tiriac; Eric A Collisson; Frances Connor; Terry Van Dyke; Serguei Kozlov; Philip Martin; Tiffany W Tseng; David W Dawson; Timothy R Donahue; Atsushi Masamune; Tooru Shimosegawa; Minoti V Apte; Jeremy S Wilson; Beverly Ng; Sue Lynn Lau; Jenny E Gunton; Geoffrey M Wahl; Tony Hunter; Jeffrey A Drebin; Peter J O'Dwyer; Christopher Liddle; David A Tuveson; Michael Downes; Ronald M Evans
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582
View more
  1 in total

1.  PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker.

Authors:  Jérémy Nigri; Meritxell Gironella; Christian Bressy; Elena Vila-Navarro; Julie Roques; Sophie Lac; Caroline Bontemps; Coraline Kozaczyk; Jérôme Cros; Daniel Pietrasz; Raphaël Maréchal; Jean-Luc Van Laethem; Juan Iovanna; Jean-Baptiste Bachet; Emma Folch-Puy; Richard Tomasini
Journal:  Cell Mol Life Sci       Date:  2017-06-27       Impact factor: 9.261
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.